Brooklyn Investment Group
PTGX icon

Brooklyn Investment Group’s Protagonist Therapeutics PTGX Stock Holding History

Brooklyn Investment Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$519K Buy
4,925
+594
+14% +$52.6K 0.02% 991
2025
Q4 		$381K Buy
+4,331
New +$354K 0.02% 866
2025
Q3 		– Sell
-487
Closed -$26.9K – 2178
2025
Q2 		$26.9K Sell
487
-913
-65% -$43.8K ﹤0.01% 1690
2025
Q1 		$67.7K Buy
+1,400
New +$58.7K 0.01% 652

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Brooklyn Investment Group's PTGX Position: Q1 2026 in Review

Brooklyn Investment Group increased its Protagonist Therapeutics (PTGX) stake by 14% in Q1 2026, buying an estimated $52.6K and bringing the position to 4,925 shares worth $519K. The position accounts for 0.02% of the portfolio, ranked #991.

Brooklyn Investment Group first reported a position in PTGX in Q1 2025 and has held it in 4 quarters since. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Brooklyn Investment Group held 4,925 shares of Protagonist Therapeutics worth $519K as of Q1 2026.
  • Brooklyn Investment Group bought 594 Protagonist Therapeutics shares in Q1 2026, an estimated $52.6K.
  • Protagonist Therapeutics made up 0.02% of Brooklyn Investment Group's portfolio in Q1 2026, its #991 holding.
  • Brooklyn Investment Group first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.